

25. Knuuti J, Wijns W, Saraste A, et al. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. *Eur Heart J*. Jan 14 2020;41(3):407-477. doi:10.1093/eurheartj/ehz425.
26. von Arnim T. Medical treatment to reduce total ischemic burden: total ischemic burden bisoprolol study (TIBBS), a multicenter trial comparing bisoprolol and nifedipine. *The TIBBS Investigators. J Am Coll Cardiol*. Jan 1995;25(1):231-8. doi:10.1016/0735-1097(94)00345-q.
27. Bangalore S, Steg G, Deedwania P, et al. beta-Blocker use and clinical outcomes in stable outpatients with and without coronary artery disease. *JAMA*. Oct 3 2012;308(13):1340-9. doi:10.1001/jama.2012.12559.
28. Sabido M, Thilo H, Guido G. Long-term effectiveness of bisoprolol in patients with angina: A real-world evidence study. *Pharmacol Res*. Jan 2019;139:106-112. doi:10.1016/j.phrs.2018.10.031.
29. Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. *BMJ*. May 19 2009;338:b1665. doi:10.1136/bmj.b1665.
30. Smith C, Teitler M. Beta-blocker selectivity at cloned human beta 1- and beta 2-adrenergic receptors. *Cardiovasc Drugs Ther*. Apr 1999;13(2):123-6. doi:10.1023/a:1007784109255.
31. Ceconi C, Francolini G, Olivares A, et al. Angiotensin-converting enzyme (ACE) inhibitors have different selectivity for bradykinin binding sites of human somatic ACE. *Eur J Pharmacol*. Dec 22 2007;577(1-3):1-6. doi:10.1016/j.ejphar.2007.07.061.
32. Fox KM, Investigators EUtOrocewPiscAd. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). *Lancet*. Sep 6 2003;362(9386):782-8. doi:10.1016/s0140-6736(03)14286-9.
33. Bertrand ME, Ferrari R, Remme WJ, et al. Perindopril and beta-blocker for the prevention of cardiac events and mortality in stable coronary artery disease patients: A European trial on Reduction Of cardiac events with Perindopril in stable coronary Artery disease (EUROPA) subanalysis. *Am Heart J*. Dec 2015;170(6):1092-8. doi:10.1016/j.ahj.2015.08.018.
34. Brugts JJ, Bertrand M, Remme W, et al. The Treatment Effect of an ACE-Inhibitor Based Regimen with Perindopril in Relation to Beta-Blocker use in 29,463 Patients with Vascular Disease: a Combined Analysis of Individual Data of ADVANCE, EUROPA and PROGRESS Trials. *Cardiovasc Drugs Ther*. Aug 2017;31(4):391-400. doi:10.1007/s10557-017-6747-9.
35. Castellano JM, Pocock SJ, Bhatt DL, et al. Polypill Strategy in Secondary Cardiovascular Prevention. *N Engl J Med*. Sep 15 2022;387(11):967-977. doi:10.1056/NEJMoa2208275.

**S NÁMI SE NEZTRATÍTE**

Časopis je indexován v těchto databázích:

Scopus, Ebsco, Embase a Bibliographia medica čechoslovaca

Využíváme systém **CrossRef**. S články můžete snadno pracovat díky jednoznačnému identifikátoru **DOI**.

